Schizophrenia Bulletin
Index—1982-83

Author Index

A
Anderson, G.M.; see Young, J.G.

B
Baldessarini, R.J.; see Donaldson, S.R.
Bartko, J.J.; see Carpenter, W.T., Jr.
Berner, P.; see Schanda, H.
Brundage, B.E. First person account: What I wanted to know but was afraid to ask, 9(4):583-585, 1983.

Buckley, P. Identifying schizophrenic patients who should not receive medication, 8(3):429-432, 1982.

C
Detlor, J.; see Young, J.G.
D
Cohen, D.J.; see Abbott, D.
Cohen, D.J.; see Harcherik, D.F.
Cohen, D.J.; see Hunt, R.D.
Cohen, D.J.; see Jagger, J.
Cohen, D.J.; see Paul, R.
Cohen, D.J.; see Young, J.G.
Cohen, P.; see Engelhardt, D.M.
Dibble, E.; see Schulz, P.M.
Dysken, M.W.; see Mueser, K.T.

E
Engelhardt, J.A.Z.; see Engelhardt, D.M.
Erlenmeyer-Kimling, L.; see Friedman, D.

F
Faber, R. Letter to the editor, 8(4):594, 1982.
Falloon, I.R.H.; see Vaughn, C.E.
Farkas, M.; see Anthony, W.A.
Feiz, R.; see Young, J.G.
Feldman, J.; see Engelhardt, D.M.
Fogg, L.; see Lewine, R.R.J.
Friedman, D.; see Vaughn, C.E.

G
Gabriel, E.; see Schanda, H.
Garbutt, J.C., and van Kammen, D.P.
Garbutt, J.C.; see Wilson, I.C.
Golenberg, A.J.; see Donaldson, S.R.
Genel, M.; see Abbott, D.
Genel, M.; see Young, J.G.
Gershon, E.S.; see Schulz, P.M.
Guy, M.P.; see Guy, J.D.

H
Harcherik, D.F.; see Young, J.G.
Heinrichs, D.W.; see Carpenter, W.T.; Jr.
Hersh, S.; see Summers, F.
Hollister, L.E.; see Csernansky, J.G.
Holman, C.; see Csernansky, J.G.
Holzman, P.S.; see Levy, D.L.
Holzman, P.S.; see Lipton, R.B.
Hunt, R.D.; see Young, J.G.

I

J
John, K.; see Jagger, J.
Jones, S.; see Vaughn, C.E.

K
Kavanagh, M.E.; see Young, J.G.
Keith, S.J.; see Maser, J.D.
Kendell, R.E. Comments on Blashfield's article, 8(1):11-12, 1982.
Kidd, K.K.; see Jagger, J.
Kidd, K.K.; see Pauls, D.L.
Kronberger, M.-L.; see Schanda, H.
Küfferle, B.; see Schanda, H.
Kyprie, R.M.; see Young, J.G.

L
Lanier, C.F.; see Wilson, I.C.
Lanin-Kettering, I.; see Harrow, M.
Larson, J.; see Spohn, H.E.
Leckman, J.F.; see Young, J.G.
Levin, S.; see Lipton, R.B.
Levy, D.L.; see Lipton, R.B.
Lewine, R.R.J. Overview and reflections.
Monk, A.F.; see Calev, A.
Monteiro, A.; see Jenner, F.A.
Moylan, J.; see Wilson, I.C.

N
Nelson, W.; see Wilson, I.C.
Norwind, B.L. Developing an enforceable "right to treatment" theory for the chronically mentally disabled in the community, 8(4):642–651, 1982.

P
Petersen, R. What are the needs of chronic mental patients?, 8(4):610–616, 1982.
Potkin, S.G.; see Cannon-Spoor, H.E.
Prange, A.J., Jr.; see Wilson, I.C.
Proctor, L.R.; see Levy, D.L.
Prosen, M.; see Harrow, M.
Prusoff, B.A.; see Jagger, J.
Pyke-Lees, P.; see Pringle, J.

R
Rosen, B.; see Engelhardt, D.M.
Roth, J.A.; see Young, J.G.
Rottem, D.; see Abbott, D.

S
Schechterman, J.; see Worland, J.
Schulz, S.C.; see Schulz, P.M.
Shaywitz, B.A.; see Harcherik, D.F.
Shaywitz, B.A.; see Hunt, R.D.
Shaywitz, B.A.; see Young, J.G.
Shaywitz, S.E.; see Harcherik, D.F.
Shaywitz, S.E.; see Hunt, R.D.
Shaywitz, S.E.; see Young, J.G.
Silverman, L.H.; see Mendelsohn, E.
Snyder, K.S.; see Vaughn, C.E.
Spohn, H.E.; see Schoeller, C.
Sprague, M.M.; see Young, J.G.
St. Claire Evans, M.; see Carpenter, W.T., Jr.
Strauss, J.S. Comments on Blashfield's article, 8(1):8–9, 1982.

T
Targum, S.D.; see Schulz, P.M.

V
van Kammen, D.P.; see Garbutt, J.C.
van Kammen, D.P.; see Schulz, P.M.
Vaughan, H.G., Jr.; see Friedman, D.

Venables, P.H.; see Calev, A.

von Zerssen, D.; see Möller, H.-J.

Wagner, R.L.; see Weinberger, D.R.

Waldo, M.C.; see Young, J.G.

Wallace, C.J.; see Guy, J.D.


Weeks, D.G.; see Worland, J.


Weiner, S.M.; see Worland, J.

Werner-Eilert, K.; see Möller, H.-J.

Willis, M.J. The impact of schizophrenia on families: One mother’s point of view, 8(4):617-619, 1982.


Wüchner-Stockheim, M.; see Möller, H.-J.

Wyatt, R.J.; see Cannon-Spoor, H.E.

Wyatt, R.J.; see Weinberger, D.R.


Young, J.G.; Feiz, R.; Roth, J.A.; Waldo, M.C.; and Cohen, D.J. Catecholamine-thyroid hormone interactions: I. Thyroid hormone and platelet MAO activity in psychiatrically disturbed children, 8(2):297-300, 1982.


Young, J.G.; Sprague, M.M.; Cohen, D.J.; Roth, J.A.; and Genel, M. Catecholamine-thyroid hormone interactions: II. Thyroid hormone and platelet MAO activity in patients with thyroid disorders, 8(2):301-305, 1982.

Young, J.G.; see Anderson, G.M.

Subject Index

A
Abnormal Involuntary Movement Scale (AIMS), 9:187

Age
Eye tracking, schizophrenia, 9:13, 9:37
Minnesota Multiphasic Personality Inventory (MMPI), schizophrenia, 9:226
Neuropsychiatric assessment, children, 8:349
Psychiatric chronicity, 9:122
Social behavior, posttreatment, 8:85
Vestibular reactivity, children, 9:383

Affective Disorders
Dichotic listening, schizophrenia, affective disorders, 9:134
IQ, children of parents with affective disorders, 8:135
Psychotic syndromes, pattern of symptom remission, 9:95

Anomalies, Minor, Physical, in schizophrenia, 9:571

Anxiety
Social skills training, 8:69

 Aphasia
Pseudo-depression in schizophrenia, 8:118; (letter) 8:594

Attention
Evoked potentials in children at risk for schizophrenia, 8:514
Eye tracking in schizophrenia, 9:13; 9:37
Neuropsychiatric assessment, children, 8:349
Reaction time, children at risk for schizophrenia, 8:514
Tourette's syndrome, vigilance tracking task, 8:356

Attention Deficit Disorder
Clonidine therapy, 8:236
Diagnostic criteria, 8:236
Eye tracking deficits, 9:50
Family and genetic studies, 8:236
Methylphenidate pharmacokinetics, 8:236
Social behavior, 8:236

Atypical Psychoses
Genetic study of relatives of patients with paranoid psychoses, 9:563

Autism. See Infantile Autism

Autobiographical Accounts
Chronic mental patients, 8:610
Expectations and the recovery process, 8:605
A father's thoughts, 9:439
A glimpse of light in the dark, 9:284
Impact of schizophrenia on families: One mother's point of view, 8:617
A pharmacy student's view, 9:152
Poetry, 8:552
Posthospital adjustment, 8:548
What I wanted to know but was afraid to ask, 9:583

Biochemical factors
Adenylate cyclase, schizophrenia, 8:438
Amine metabolites, cerebrospinal fluid, autistic children, 8:205
Catecholamine metabolites, schizophrenia, 8:438
Catecholamines, plasma and urinary, infantile autism, 8:205
Clonidine challenge, infantile autism, 8:205
Dopamine hypothesis, 8:438; 8:595; 9:325; 9:555
Dopamine, post-mortem brains of schizophrenics, 8:438
Dopamine receptor sensitivity, schizophrenia, 8:438
Dopamine-beta-hydroxylase, infantile autism, 8:205
Dopamine-beta-hydroxylase, schizophrenia, 8:438
Dopamine-beta-hydroxylase, thyroxine, children with psychiatric disorders, 8:306
Environmental factor interaction model, 8:435
Etiology of schizophrenia, parents' perception, 8:504
Gamma-aminobutyric acid, cerebrospinal fluid, schizophrenia, 9:336
Gamma-aminobutyric acid, dopamine interactions, schizophrenia, 9:336
Gamma-aminobutyric acid (GABA), GABA receptor binding, schizophrenic brain, 9:336
Glutamic acid decarboxylase, schizophrenic brain, 9:336
High performance liquid chromatography methodology, 8:333
Homovanillic acid, cerebrospinal fluid, attention deficit disorder, 8:236
Homovanillic acid, cerebrospinal fluid, autistic children, 8:205
Homovanillic acid, post-mortem brains of schizophrenics, 8:438
Human growth hormone, attention deficit disorder, 8:236
Human growth hormone, neuroleptics in schizophrenia, 8:236
5-Hydroxyindoleacetic acid, cerebrospinal fluid, attention deficit disorder, 8:236
5-Hydroxyindoleacetic acid, cerebrospinal fluid, autistic children, 8:205
3-Methoxy-4-hydroxyphenethyleneglycol, attention deficit disorder, 8:236
3-Methoxy-4-hydroxyphenethyleneglycol, cerebrospinal fluid, autistic children, 8:205
Methylphenidate pharmacokinetics, attention deficit disorder, 8:236
Monoamine oxidase, attention deficit disorder, 8:236
Monoamine oxidase, platelets, thyroxine, children with psychiatric disorders, 8:297
Monoamine oxidase, platelets, thyroxine, children with thyroid disorders, 8:297
Monoamine oxidase activity, platelets, schizophrenia, 8:438
Neuroendocrinology, dopaminergic activity assessment, schizophrenia, 8:438
Probenecid blockade, autism, 8:205
Serotonin, attention deficit disorder, 8:236
Temporal lobe epilepsy, dopaminergic supersensitivity, 9:325
Thyroxine, children with psychiatric disorders, 8:297
Tyrosine hydroxylase, schizophrenia, 8:438

Caloric Stimulation. See Vestibular Dysfunction

Catatonia
Opioid antagonists in schizophrenia, 9:213

Cerebellar Atrophy in Schizophrenia
Computed tomography scans, 9:193; 9:265
Vermis measurement, post-mortem brains, 9:193
Vestibular dysfunction, 9:383

Cerebrospinal Fluid
Gamma-aminobutyric acid in schizophrenia, 9:336
High performance liquid chromatography methodology, 8:333
Homovanillic acid, attention deficit disorder, 8:236
Homovanillic acid, schizophrenia, 8:438
Probenecid blockade, amine metabolites, children, 8:205

Cognition
Evoked potentials, children at risk for schizophrenia, 8:514
Memory pathology, schizophrenia, 9:247
Neuropsychiatric assessment, children, 8:349
Social skills training, 8:69
Tardive dementia, schizophrenia, 9:187
Thought disorder, speech disorder, schizophrenia, 8:587

Communication
Developmental disorders of language, 8:279
Speech disorder and thought disorder, 8:587

Community Psychiatry
Case management, chronically mentally disabled, 8:655
Dissatisfaction with mental health system, 8:652
Family evaluation of mental health professionals, 8:626
National Schizophrenia Fellowship, 8:620
Pharmacotherapy, psychosocial therapy interaction, 9:543
Right to treatment, 8:642

Community Support Systems
Definition, operational, 8:39
Outcome assessment, 8:39

Computed Tomography in Schizophrenia, 9:193; 9:265
Premorbid adjustment, 8:470

Definitions
What is schizophrenia, opinions from authorities, 8:433; 8:595; 9:7; 9:331; 9:495

Deinstitutionalization
Hospitalization rates, schizophrenia, 8:493
Outcome assessment, 8:39

Delusions
Paranoid psychoses, first degree relatives, 9:563

Dementia
Tardive dementia, schizophrenia, 9:187

Depression
Postpsychotic depression, schizophrenia, 8:118
Pseudo-depression, schizophrenia, 8:118; (letter) 8:594
Schizophrenic or paranoid psychoses, 8:109

Development
Motor skills, normal children, 8:349
Neuropsychiatric assessment, 8:349
Premorbid Adjustment Scale, schizophrenia, 8:470
Schizophrenia, triggering life events, 8:600
Tourette's children, motor skills, 8:356

Diagnostic Criteria
Assessment, children, 8:205
Attention deficit disorder, 8:236
Citation analysis, Feighner et al. article, 8:1; (letters) 8:592
DSM-III, Minnesota Multiphasic Per-
sonality Inventory, schizophrenia, 9:226
DSM-III criteria, symptoms of Kraepelin and Bleuler, 8:597
Evoked potentials, diagnostic specificity, 8:514
Eye tracking, 9:50
Feighner criteria, 8:1
Invisible college, 8:1
Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226
Research Diagnostic Criteria, 8:1
Tourette’s syndrome, 8:267

Diagnostic Interview Schedule
Lifetime psychotic symptom assessment, 9:377

Dichotic Listening. See Hemispheric Processing

Dreams, Hallucinogenic Drug States, and Schizophrenia, 9:73

Drug Therapy. See Pharmacotherapy

Dyskinesia, Tardive
Abnormal Involuntary Movement Scale (AIMS), emotional behavior, schizophrenia, 9:187
Children, neuroleptic withdrawal, 8:320
Dementia, schizophrenia, 9:187
Dopamine receptor supersensitivity, 9:555
Low dose neuroleptics, outcome on Simpson Scale, 9:528

Ethics of Research
Child psychiatry, 8:205

Evoked Potentials
Children at risk for schizophrenia, 8:514

Eye Tracking
Assessment of dysfunction, 9:44
Computed tomography, schizophrenia, 9:265
Editorial introduction, 9:11
Methodological consensus: Workshop contributions, 9:33

Review of eye movement dysfunction, 9:13
Saccadic movements and multilevel control, 9:55

F

Family Studies
Attention deficit disorder, 8:236
Eye tracking, schizophrenia, 9:13
Family attitudes, schizophrenia, 8:504; 8:626
IQ, children of parents with schizophrenia, 8:135

Family Treatment
Supportive family counseling, 8:634

Genetics
Attention deficit disorder, 8:236
Childbearing attitudes, patients with schizophrenia, 8:504
Childhood behavioral traits, 8:253
Counseling, family attitudes, schizophrenia, 8:504
Evoked potentials, children at risk for schizophrenia, 8:514
Eye tracking, schizophrenia, 9:13
Organomorphic patients’ first-degree relatives, 9:563
Paranoid psychoses, first-degree relatives, 9:563
Stuttering, 8:253
Tourette’s syndrome, 8:253

Global Assessment Scale
Outcome assessment, schizophrenic or paranoid psychoses, 8:99

H

Hallucinations
Diagnostic Interview Schedule, Present State Examination, compared, 9:377
Dreams, drug states, schizophrenia, 9:73
Opioid antagonists, schizophrenia, 9:213
Outcome, Global Assessment Scale, Inpatient Multidimensional Psychiatric Scale, 8:99

Hemispheric Processing
Computed tomographic measurement, asymmetries, schizophrenia, 9:193; 9:265
Dichotic listening, schizophrenia, affective illness, 9:134
Motor skills, normal children, 8:349
Staggered Spondaic Word Test in psychosis, 9:134

Heterogeneity
Dichotic listening, schizophrenia, affective illness, 9:134
Dopamine receptor binding, dynamic change, schizophrenia, 8:325
Evoked potentials, high-risk children, 8:514
Genetic study, relatives of patients with paranoid psychoses, 9:563
Multiple central nervous system abnormalities, 8:433
Neuroleptic response, schizophrenia, 8:429
Pharmacotherapeutic response, 9:504

High Performance Liquid Chromatography (HPLC)
Measurement of neurochemistry, 8:333

Hippocampus, Atrophy in Schizophrenia, 9:193

Infantile Autism
Amine metabolites, cerebrospinal fluid, 8:205
Catecholamines, plasma, urine, 8:205
Clonidine challenge, 8:205
Dopamine-beta-hydroxylase, 8:205
Psychophysiology, 8:205

Information Processing
Social skills training, 8:62

Inpatient Multidimensional Psychiatric Scale (IMPS)
Depression, schizophrenia, 8:100
Outcome assessment, schizophrenic or paranoid psychoses, 8:99

Katz Adjustment Scales and psychiatric chronicity, 9:122

Language. See Communication

Laterality. See Hemispheric Processing

Lysergic Acid Diethylamide, PGO waves and hallucinations, 9:73

Math

K

Katz Adjustment Scales and psychiatric chronicity, 9:122

L

Language. See Communication

Laterality. See Hemispheric Processing

Lysergic Acid Diethylamide, PGO waves and hallucinations, 9:73

M

Memory. See Cognition

Minnesota Multiphasic Personality Inventory (MMPI), schizophrenia, 9:226

Monoamine Oxidase

Attention deficit disorder, platelet activity, 8:236
Inhibitors, clinical effects, schizophrenia, 8:438
Schizophrenia, platelet activity, 8:438
Thyroxine, children with psychiatric disorders, 8:297
Thyroxine, children with thyroid disorders, 8:297

N

Neuroleptics

Aphanisis, schizophrenia, 8:118
Computed tomographic measures of ventricular enlargement, neuroleptics, 9:265
Dopamine receptor supersensitivity reviewed, 9:555
Eye tracking, schizophrenia, 9:13; 9:37
Human growth hormone, methylphenidate, schizophrenia, 8:236
Low dose neuroleptics, outcome, 9:528
Nonresponders to neuroleptics, symptom differences, 8:429
Pseudo-depression, schizophrenia, 8:118
Receptor binding, post-mortem brains of schizophrenics, 8:438
Seizure threshold, children treated with neuroleptics, 8:320
Symptom remission pattern, treatment response, 9:95
Tardive dementia, schizophrenia, 9:187
Tardive dyskinesia, low dose neuroleptics, 9:528
Time-limited pharmacotherapy, patients followed drug free, 9:533

Neurological Impairment and minor physical anomalies in schizophrenia, 9:571

Neuropathology in Schizophrenia, 9:193

Nystagmus Abnormalities in Schizophrenia, 9:383

Onset Age and minor physical anomalies, 9:571

Opioid Peptides

Naloxone and naltrexone treatment of schizophrenia, 9:213

Outcome

Antipsychotic medication, social behavior, 8:85
Burn-out, postpsychotic depression, schizophrenia, 8:118
Childbearing attitudes, patients with schizophrenia, 8:504
Community support systems, 8:39
Demographic characteristics, 9:122
Disability, most troubling characteristics rated by patients, parents, and siblings, 8:504
First-rank symptoms, multiple regression, 9:1
Global Assessment Scale, impairment, symptoms, 8:99
Hallucinations, excitement, 8:99
Hospitalization, chronic schizophrenia, 8:493
Hospitalization length, premorbid adjustment in schizophrenia, 8:470; 8:493
Hospitalization rates, schizophrenia, 8:493
Lifetime psychotic symptom assessment, Diagnostic Interview Schedule, 9:377
Measurement instruments, 8:13
Neuroleptics, nonresponse or deterioration, 8:429
Paranoid psychoses, prediction, 8:99
Phillips Prognostic Rating Scale, 8:470
Postsychotic depression, schizophrenia, 8:118
Preadmission hospitalization history, 8:493
Recovery from schizophrenia, patterns of psychosis, 9:95
Self-ratings, schizophrenic or paranoid psychoses, 8:99
Skills training, 8:13; 8:69
Social adjustment, 8:85; 8:99
Time-limited pharmacotherapy, patients followed drug free, 9:533

Pervasive Developmental Disorders

Neuroleptic treatment, 8:320
Seizure threshold, children treated with neuroleptics, 8:320
Tardive dyskinesia, children with neuroleptic withdrawal, 8:320

PGO Waves and hallucinogenic drug states, 9:73

Pharmacotherapy

Alpha-methyl-para-tyrosine (AMPT), schizophrenia, 8:438
Amphetamine, schizophrenic children, 8:320
Antidepressants, schizophrenia, 9:504
Baclofen trials, schizophrenia, 9:336
Benzodiazepines, schizophrenia, 9:504
Carbamazepine, schizophrenia, 9:504
Clonidine, attention deficit disorder, 8:236
Clonidine, schizophrenia, 9:504
Clonidine, Tourette's syndrome, 8:205
Depression, neuroleptics, schizophrenia, 8:109
Dopamine agonists, review of clinical effects, schizophrenia, 8:438
Eye tracking, schizophrenia, 9:13
GABAergic drug trials, schizophrenia, 9:336
Haloperidol, pervasive developmental disorders, 8:320
Haloperidol, Tourette's syndrome, 8:267
Human growth hormone treatment of hypopituitary children, 8:310
L-Dopa, schizophrenic children, 8:320
Lithium, pervasive developmental disorders, 8:320
Lithium, schizophrenia, 9:504
Low dose neuroleptics, outcome, 9:528
Methylphenidate pharmacokinetics, attention deficit disorder, 8:236
Minnesota Multiphasic Personality Inventory, schizophrenia, treatment response, 9:226
Monoamine oxidase inhibitors, schizophrenia, 8:438
Naloxone, schizophrenia, 9:213
Naltrexone, schizophrenia, 9:213
Neuroleptics, depression, schizophrenia, 8:109
Neuroleptics, nonresponse or deterioration, 8:429
Neuroleptics, pervasive developmental disorders, 8:320
Neuroleptics reviewed, 9:504
Outcome measurement, 8:13
Pharmacokinetics, neuroleptics in children, 8:320
Propranolol, schizophrenia, 9:504
Psychosocial therapy interaction, 9:543
Social behavior, neuroleptics, 8:85
Tardive dyskinesia, children with neuroleptic withdrawal, 8:320
Time-limited pharmacotherapy, patients followed drug free, 9:333
Tourette's syndrome, haloperidol, 8:267
Pneumoencephalographic Studies in Schizophrenia, 9:193
Positive/Negative Symptoms
Nurses Observation Scale for Inpatient Evaluation (NOSIE) for assessment, 9:368
Recovery from schizophrenia and patterns of psychosis, 9:95
Reliability, temporal stability, Schedule for Affective Disorders-Change Version (SADS-C) and NOSIE assessment, 9:368
SADS-C interview, symptom assessment, 9:368
Premorbid Adjustment
Acute vs. insidious onset, schizophrenia, 8:470
Computed tomography, schizophrenia, 8:470
Phillips Prognostic Rating Scale, 8:470
Premorbid Adjustment Scale (PAS), schizophrenia, 8:470
Premorbid function, minor physical anomalies, schizophrenia, 9:571
Process/Reactive Dimension and minor physical anomalies in schizophrenia, 9:571
Psychophysiology
Attention deficit disorder, 8:236
Electroencephalographic abnormalities, Tourette's syndrome, 8:267
Evoked potentials, children at risk for schizophrenia, 8:514
Eye tracking, schizophrenia, 9:11
Infantile autism, 8:205
Smooth pursuit eye movements, schizophrenia, 9:11
Psychotic Experience
Fantasy activation, thought disorder, 8:532
Race
Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226
RAPID Eye Movement (REM) Sleep
Dreams, hallucinogenic drug states, and schizophrenia, 9:73
Rehabilitation
Community support systems, 8:39
Measurement instruments, 8:13; 8:39
Skills training measures, 8:13
Research
Child psychiatry, methods and strategies, 8:201; 8:205; 8:236; 8:253
Interview reliability, 8:485
Narrative information, consensus ratings, 8:485
Neuropsychiatric assessment, childhood, 8:201
Self-rating/observer rating correlations, 8:485
Social skills instruments, tabular listing, 8:62
Structured psychiatric interviews, 8:485
Symptom rating concordance, 8:485
Yale Neuropsychoeducational Assessment Scale, scoring forms, description, 8:360
Schizoaffective Psychoses
IQ in children of patients, 8:135
Schizophrenic Process
Definition of schizophrenia, 9:7
Fantasy and thought disorder, 8:532
Symptom remission patterns, 9:95
Schizophrenic Subtypes
Computed tomography, schizophrenia, 9:265
Premorbid Adjustment Scale (PAS), schizophrenia, 8:470
Sex Differences
Homovanillic acid, cerebrospinal fluid, children, 8:205
IQ, children of ill mothers and ill fathers with schizophrenia, 8:135
Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226
Motor skills, normal children, 8:349
Verbal behavior, intermingling, schizophrenia, 9:354
Social Behavior
Adjustment, Global Assessment Scale, 8:99
Antipsychotic medication, 8:85
Attention deficit disorder, 8:236
Demographic characteristics, psychiatric chronicity, 9:122
Interaction observations, 8:85
Low dose neuroleptics, social adjustment, 9:528
Measurement technology, 8:62

S
Schizoaffective Psychoses
IQ in children of patients, 8:135
Schizophrenic Process
Definition of schizophrenia, 9:7
Fantasy and thought disorder, 8:532
Symptom remission patterns, 9:95
Schizophrenic Subtypes
Computed tomography, schizophrenia, 9:265
Premorbid Adjustment Scale (PAS), schizophrenia, 8:470
Sex Differences
Homovanillic acid, cerebrospinal fluid, children, 8:205
IQ, children of ill mothers and ill fathers with schizophrenia, 8:135
Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226
Motor skills, normal children, 8:349
Verbal behavior, intermingling, schizophrenia, 9:354
Social Behavior
Adjustment, Global Assessment Scale, 8:99
Antipsychotic medication, 8:85
Attention deficit disorder, 8:236
Demographic characteristics, psychiatric chronicity, 9:122
Interaction observations, 8:85
Low dose neuroleptics, social adjustment, 9:528
Measurement technology, 8:62
Resocialization program for chronic schizophrenics, 8:85
Tourette's syndrome, 8:267

Social Class
IQ, children of patients with schizophrenia, 8:135

Social Skills Training
Assessment, 8:13, 8:62
Nonverbal elements, 8:62
Pharmacotherapy, psychosocial therapy interaction, 9:543

Statistics
First-rank symptoms, multiple regression, 9:1
Rasch model, positive/negative symptom assessment, 9:368

Subtypes; see also Schizophrenic Subtypes
Paranoid psychoses, outcome prediction, 8:99

Symptoms Checklist (SCL)-90 and psychiatric chronicity, 9:122

Tardive Dyskinesia. See Dyskinesia, Tardive

Thought Disorder
Demographic variables, verbal behavior, 9:354
Fantasy activation, 8:532
Intermingling, loss of set, schizophrenia, 9:354
Speech disorder, nonspeech disorder, 8:587
Verbal behavior, schizophrenia, 9:354

Thyroid Function
Adrenergic system modulation, 8:294
Dopamine-beta-hydroxylase, thyroxine, children with psychiatric disorders, 8:306
Monoamine oxidase, platelets, thyroxine, 8:297

Tourette's Syndrome
Attention, vigilance tracking task, 8:356
Clinical assessment instruments, 8:205
Clonidine treatment, 8:205
Cognitive function, 8:356
Epidemiology, 8:267
Genetic analysis, 8:253; 8:267
Haloperidol treatment, 8:267
Symptomatology, 8:267
Wechsler Intelligence Scale for Children (WISC) subtests, 8:356

Twin Studies
Eye tracking, schizophrenia, 9:13


Verbal Behavior. See Thought Disorder

Vestibular Dysfunction in Schizophrenia, 9:383

Vulnerability
Evoked potentials in children at risk for schizophrenia, 8:514
Life events and development, 8:600
Pharmacotherapy and psychosocial therapy interaction, 9:543

Wechsler Adult Intelligence Scale (WAIS)
Physical anomalies in schizophrenia, 9:571
Psychological functioning in resocialization program for chronic schizophrenics, 8:85

Wechsler Intelligence Scale for Children (WISC)
Offspring of families with one schizophrenic parent, 8:135

What Is Schizophrenia?
Opinions from authorities, 8:433; 8:595; 9:7; 9:331; 9:495

Yale Neuropsychoeducational Assessment Scales, 8:372